Stockreport

Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF Therapeutics, Inc. (NASDAQ:SYRE) announced positive interim Phase 1 results for SPY003, which is its novel, half-life extended Anti-IL-23 antibody. The treatment is bein [Read more]